AI transition urgency rises as trials accelerate
LISTEN
Direct audio file (MP3)More cure work is moving through the pipeline: global active cure-related trials now total 21,156, while 21 new Wire signals and 1 new Cure research item arrived in the last 24 hours. On the Cure side, CMS’s Dermavon subsidiary secured an NMPA approval in China for Lumirix® (ruxolitinib phosphate cream) to treat mild-to-atopic dermatitis, extending use of an existing targeted therapy into a new indication. On the Wire side, Gates’ signal centers on timing: the AI era will be turbulent, and whether the world is prepared enough determines how the transition lands into the “window” for major progress. Taken together, the data suggests execution momentum in medicine, alongside a societal-tempo risk in AI—making preparation decisions as consequential as lab decisions. The window is still open.
Gates warned that AI choices now will shape the transition and that the world is not preparing fast enough.
If preparation lags, society may stumble during the AI transition, slowing the translation of breakthroughs into broad human benefit.
Watch for concrete readiness actions tied to AI governance and deployment choices—because timing, per Gates, is the variable that can close the window.